<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131112">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01889277</url>
  </required_header>
  <id_info>
    <org_study_id>MT-3995-J03</org_study_id>
    <nct_id>NCT01889277</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic Nephropathy</brief_title>
  <official_title>A Phase II, Randomised, Double-blind, Placebo-controlled Study of MT-3995 in Subjects With Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of
      MT-3995 in Subjects with Diabetic Nephropathy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Frequency and nature of treatment-emergent adverse events and serious adverse events.</measure>
    <time_frame>20 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of MT-3995 and its major metabolite</measure>
    <time_frame>20 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Urine albumin-to-creatinine ratio (UACR) and blood pressure</measure>
    <time_frame>20 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>MT-3995-Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MT-3995-Low Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MT-3995-High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MT-3995-High Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-3995-Low</intervention_name>
    <arm_group_label>MT-3995-Low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-3995-High</intervention_name>
    <arm_group_label>MT-3995-High</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with Type 2 diabetes mellitus and diabetic nephropathy, who have been
             treated with a stable dose of angiotensin converting enzyme-inhibitor (ACE-I) or
             angiotensin II receptor blocker (ARB)

          -  Glycosylated haemoglobin (HbA1c) ≤10.5%

          -  Subject with albuminuria

        Exclusion Criteria:

          -  History of Type 1 diabetes, pancreas or β-cell transplantation, or diabetes secondary
             to pancreatitis or pancreatectomy.

          -  Serum potassium level &lt;3.5 or &gt;5.0 mmol/L

          -  Subjects who had acute kidney injury within 3 months prior to baseline or have
             undergone hemodialysis at any time prior to randomisation

          -  Subjects with clinically significant hypotension
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masaomi Nangaku, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Division of Nephrology and Endocrinology University of Tokyo School of medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kazuoki Kondou, Adviser</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Information Desk</last_name>
    <email>cti-inq-ml@ml.mt-pharma.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Koukan Hospital</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa Pref.</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 11, 2014</lastchanged_date>
  <firstreceived_date>June 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Nephropathy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
